BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 15608037)

  • 21. Comparison of GnRH agonists and antagonists in assisted reproduction cycles of patients at high risk of ovarian hyperstimulation syndrome.
    Ragni G; Vegetti W; Riccaboni A; Engl B; Brigante C; Crosignani PG
    Hum Reprod; 2005 Sep; 20(9):2421-5. PubMed ID: 15890731
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro fertilization cycle outcome after coasting in gonadotropin-releasing hormone (GnRH) agonist versus GnRH antagonist protocols.
    Farhi J; Ben-Haroush A; Lande Y; Sapir O; Pinkas H; Fisch B
    Fertil Steril; 2009 Feb; 91(2):377-82. PubMed ID: 18321490
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of a gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist flare-up regimen in poor responders undergoing ovarian stimulation.
    Malmusi S; La Marca A; Giulini S; Xella S; Tagliasacchi D; Marsella T; Volpe A
    Fertil Steril; 2005 Aug; 84(2):402-6. PubMed ID: 16084881
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recombinant luteinizing hormone supplementation to recombinant follicle-stimulating hormone induced ovarian hyperstimulation in the GnRH-antagonist multiple-dose protocol.
    Griesinger G; Schultze-Mosgau A; Dafopoulos K; Schroeder A; Schroer A; von Otte S; Hornung D; Diedrich K; Felberbaum R
    Hum Reprod; 2005 May; 20(5):1200-6. PubMed ID: 15665010
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Short gonadotropin-releasing hormone agonist versus flexible antagonist versus clomiphene citrate regimens in poor responders undergoing in vitro fertilization: a randomized controlled trial.
    Schimberni M; Ciardo F; Schimberni M; Giallonardo A; De Pratti V; Sbracia M
    Eur Rev Med Pharmacol Sci; 2016 Oct; 20(20):4354-4361. PubMed ID: 27831635
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparisons of different dosages of gonadotropin-releasing hormone (GnRH) antagonist, short-acting form and single, half-dose, long-acting form of GnRH agonist during controlled ovarian hyperstimulation and in vitro fertilization.
    Hsieh YY; Chang CC; Tsai HD
    Taiwan J Obstet Gynecol; 2008 Mar; 47(1):66-74. PubMed ID: 18400585
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. The European Orgalutran Study Group.
    Borm G; Mannaerts B
    Hum Reprod; 2000 Jul; 15(7):1490-8. PubMed ID: 10875855
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized single-blind controlled trial of letrozole as a low-cost IVF protocol in women with poor ovarian response: a preliminary report.
    Goswami SK; Das T; Chattopadhyay R; Sawhney V; Kumar J; Chaudhury K; Chakravarty BN; Kabir SN
    Hum Reprod; 2004 Sep; 19(9):2031-5. PubMed ID: 15217999
    [TBL] [Abstract][Full Text] [Related]  

  • 29. GnRH antagonist versus long GnRH agonist protocol in poor IVF responders: a randomized clinical trial.
    Prapas Y; Petousis S; Dagklis T; Panagiotidis Y; Papatheodorou A; Assunta I; Prapas N
    Eur J Obstet Gynecol Reprod Biol; 2013 Jan; 166(1):43-6. PubMed ID: 23020996
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Luteal-phase ovarian stimulation is a feasible method for poor ovarian responders undergoing in vitro fertilization/intracytoplasmic sperm injection-embryo transfer treatment compared to a GnRH antagonist protocol: A retrospective study.
    Wei LH; Ma WH; Tang N; Wei JH
    Taiwan J Obstet Gynecol; 2016 Feb; 55(1):50-4. PubMed ID: 26927248
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Minimal stimulation IVF with late follicular phase administration of the GnRH antagonist cetrorelix and concomitant substitution with recombinant FSH: a pilot study.
    Pelinck MJ; Vogel NE; Hoek A; Arts EG; Simons AH; Heineman MJ
    Hum Reprod; 2005 Mar; 20(3):642-8. PubMed ID: 15608031
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Addition of highly purified HMG after corifollitropin alfa in antagonist-treated poor ovarian responders: a pilot study.
    Polyzos NP; De Vos M; Corona R; Vloeberghs V; Ortega-Hrepich C; Stoop D; Tournaye H
    Hum Reprod; 2013 May; 28(5):1254-60. PubMed ID: 23442756
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Flexible GnRH antagonist versus flare-up GnRH agonist protocol in poor responders treated by IVF: a randomized controlled trial.
    Lainas TG; Sfontouris IA; Papanikolaou EG; Zorzovilis JZ; Petsas GK; Lainas GT; Kolibianakis EM
    Hum Reprod; 2008 Jun; 23(6):1355-8. PubMed ID: 18403419
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fixed versus flexible gonadotropin-releasing hormone antagonist administration in in vitro fertilization: a randomized controlled trial.
    Kolibianakis EM; Venetis CA; Kalogeropoulou L; Papanikolaou E; Tarlatzis BC
    Fertil Steril; 2011 Feb; 95(2):558-62. PubMed ID: 20637457
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparisons of GnRH antagonist versus GnRH agonist protocol in poor ovarian responders undergoing IVF.
    Pu D; Wu J; Liu J
    Hum Reprod; 2011 Oct; 26(10):2742-9. PubMed ID: 21778283
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Will GnRH antagonists provide new hope for patients considered 'difficult responders' to GnRH agonist protocols?
    Craft I; Gorgy A; Hill J; Menon D; Podsiadly B
    Hum Reprod; 1999 Dec; 14(12):2959-62. PubMed ID: 10601078
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Controlled ovarian stimulation using a long gonadotropin-releasing hormone antagonist protocol: a proof of concept and feasibility study.
    Weissman A; Ravhon A; Steinfeld Z; Nahum H; Golan A; Levran D
    Gynecol Obstet Invest; 2013; 76(2):113-8. PubMed ID: 23920048
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Supplementation with a recombinant human chorionic gonadotropin microdose leads to similar outcomes in ovarian stimulation with recombinant follicle-stimulating hormone using either a gonadotropin-releasing hormone agonist or antagonist for pituitary suppression.
    Cavagna M; Maldonado LG; de Souza Bonetti TC; de Almeida Ferreira Braga DP; Iaconelli A; Borges E
    Fertil Steril; 2010 Jun; 94(1):167-72. PubMed ID: 19342035
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparing GnRH agonist long protocol and GnRH antagonist protocol in outcome the first cycle of ART.
    Firouzabadi RD; Ahmadi S; Oskouian H; Davar R
    Arch Gynecol Obstet; 2010 Jan; 281(1):81-5. PubMed ID: 19357861
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Comparison of GnRH agonists and antagonists in an ovular donation program].
    Saucedo de la Llata E; Moraga Sánchez MR; Batiza Reséndiz V; Santos Haliscak R; Galache Vega P; Hernández Ayup S
    Ginecol Obstet Mex; 2004 Feb; 72():53-6. PubMed ID: 15216901
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.